Hello again Members,
We’re asking all of you to please turn your attention to MEDH.
We’re alerting this low float play as real possible high double-digit winner.
MEDH is no stranger to momentum surges as it’s been in the dollar range multiple times in its past.
Its current technical setup and charming low float gives plenty of reason to believe that that time to climb might be starting now.
Less than two weeks ago, MEDH announced it is in the process of becoming licensed as a Wholesale Distributor of Pharmaceuticals in the state of Alabama. As a result, the company has also entered into an Exclusive Marketing Agreement with B&B Consulting whose sales exceeded over 7M dollars in pharmaceutical sales in 2015. Mr. Hiltz, Managing Member of B&B Consulting has agreed to oversee the company’s pharmaceutical sales division. Mr. Hiltz stated “I am excited to join MedX Holdings, I believe that the combination of a public company and pharmaceutical sales just makes sense.”
In addition, MEDH has also secured an agreement with one of the largest FDA Manufacturers in the United States. Their first product that has been approved to sell is a 5% Lidocaine Ointment 50g jar. Negotiated price allows the company to have very competitive pricing to offer B&B’s current list of clients. 5% Lidocaine is a highly sought after analgesic ointment for the purpose of reducing and controlling pain. This comes at a time when the nation is riveting over the rising deaths occurring in epidemic proportion all resulting from the overuse of oral prescription pain medication. As a result, Physicians and other medical professionals are being forced to look at alternative solutions when treating pain.
Kathleen Roberton CEO of MedX Holdings stated, “It makes perfect sense to enter into Pharmaceutical and Nutraceutical sales as we build our portfolio of medial businesses. This will allow our company to produce its own revenue without being a burden to our acquisitions which add tangilble asset based value”.
More on that news release here:
http://finance.yahoo.com/news/medx-holdings-inc-announces-entered-120000443.html
Just last week, MEDH announced Mr. Charles Yelton R.Ph has joined the team as Vice President in charge of Nutraceutical and Pharmaceutical Development. In addition to this position as a licensed pharmacist, he will also serve as our Certified Designated Representative. Mr. Yelton has been a licensed pharmacist for over 39 years. He previously owned Carpenter Dent Drugs where he successfully grew this business from $146,000 to over 1.2M annually. After 23 years, he sold this business and went to work as a pharmacist for a major retail chain; he has worked in over 115 pharmacies throughout Kentucky and Alabama. Mr. Yelton was also the creator of Pain Doctor, an external OTC analgesic for pain distributed by ABC Pharmaceuticals.
Ms. Roberton, CEO commented: “we are very pleased to have Mr. Yelton join our team, I have personally had the pleasure of knowing him and his integrity for almost 10 years. Mr. Yelton’s experience and knowledge both as a licensed pharmacist and owner of ABC Pharmaceuticals is exactly what we needed to move forward as a licensed wholesale distributor of pharmaceuticals in many states”
Charles Yelton R.Ph, offered: “I am excited to join this talented MedX Holdings team. Together, we have the potential to create extreme dynamic sales growth very quickly. We are working with one the top pharmaceutical manufactures who holds over 105 ANDA’s which allows us to expand our projected RX lines and OTC lines very quickly.”
Their recent licensing update in that same news release updated that MEDH is in the final stages of securing a warehouse/office space in the state of Alabama as well as in the state of Florida. They will be licensed as a Wholesale Distributor of Pharmaceuticals in Alabama where Mr. Yelton works and is currently licensed. In Florida, they will ship directly to a Third Party Logistic partner who will legally ship to all of their clients in Florida. A Third Party Logistic Warehouse represents the fastest path for MedX to legally sell in the state of Florida. A 3PL does not manufacture the products, take title to own the products nor has anything to do with selling the products. Their partner will simply take possession, repackage if necessary, and then ship directly to the company’s clients.
BUSINESS SUMMARY
(MEDH - MedX Holdings, Inc.)
http://www.medxholdings.com/
MedX Holdings, Inc. or MEDH targets the acquisitions of undervalued, turnaround medical related businesses along with products and services that benefit our partners. MEDH’s mission is to provide a new form of governance enabling medical related businesses and product driven partners to take advantage of the power of a public company without losing management expertise.
MEDH is introducing, Collaborative Profit, an innovative approach that allows each acquisition to become a stand-alone subsidiary with all the advantage and power of public company while keeping their independent management control. This unique diversified platform, designed by MEDH, offers protection for both the investor and the subsidiary. It provides acquisitions the ability to raise capital and offers investors the assurance that their investment is at low risk.
The concept behind Collaborative Profit is to be mutually beneficial to all parties while leaving the control of the small business in the hands of the business owner. A management agreement transfers the rights and privileges that were in place prior to acquisition, back to the business owner. Essentially, the operations, accounts and administrative practices are in the hands of the business owner after the acquisition while MEDH manages the public company and over sees all management.
Collaboration begins at the grassroots level. From the executives that run MedX Holdings down to respected consultants that serve the company, MEDH has seasoned professionals in the Healthcare Sector and veterans in medical management, sales and practice with over 35 years of experience.
MARKET OUTLOOK
Promising news for the future was found in a thorough analysis by the leader in consensus forecasts of leading industry analysis and analysis of the pharmaceutical and biotechnology healthcare sector, EvaluatePharma.
US spend on prescription drugs is set to grow strongly following the unprecedented 50 new drugs approved in America during 2014.
Worldwide prescription drug sales are expected to reach almost one trillion dollars by 2020 (CAGR: 4.8% between 2014 and 2020).
The value of M&A transactions almost doubled to $116bn in 2014; the number of transactions increased after two years of decline.
Encouragingly for drug developers, despite the increased number of drugs approved, up from 35 in 2013, the quality of the new drugs did not slip. Eight of the top ten new drugs approved in 2014 are forecast to have sales of more than $1bn five years after launch, and included the first crop of PD-1 drugs approved in the year. Sales averaged across all 50 came in at $528m, slightly up on the $522m achieved last year. This jump in productivity has interestingly come at a time when R&D spend continues to be closely scrutinized
by large Pharma groups.
This year’s World Preview shows prescription drug sales are set to advance at almost 5% a year until 2020. Continued confidence in the sector is being driven by a number of positive fundamentals including the recent increase in R&D productivity, which has resulted in a big hike in drug approvals, and the emergence of breakout drugs such as Gilead’s Sovaldi franchise. Excitement surrounding new products including Merck & Co’s Keytruda, Bristol-Myers Squibb’s Opdivo and antiPCSK9s from Amgen and Sanofi should ensure the sales momentum continues.
For more on that outlook to 2020 click here:
http://info.evaluategroup.com/rs/607-YGS-364/images/wp15.pdf
There you have it everyone. Start your own research now, and remember to use sound money management and trading discipline. Always book a profit when you can and never risk more than you can afford to lose. The OTC markets, like all exchanges, can move quick and be volatile. Always do your due diligence.
